Jyoti Sangwan1, Sourav Sen2, Rajiv Mohan Gupta3, K Shanmuganandan4, Rajan S Grewal5. 1. Associate Professor (Microbiology), SHKM Government Medical College, Mewat, Haryana, India. 2. Professor & Head, Department of Microbiology, Armed Forces Medical College, Pune 411040, India. 3. Dean, Armed Forces Medical College, Pune 411040, India. 4. Professor of Medicine & Rheumatology, Department of General Hospital, Sree Balaji Medical College & Hospital, Chennai, India. 5. Director General Medical Services (Air), O/o DGMS (Air), IHQ, Air Headquarter, RK Puram, New Delhi 110066, India.
Abstract
BACKGROUND: Currently CD4+ T lymphocyte counts and HIV-1 RNA levels are being utilized to predict outcome of human immunodeficiency virus (HIV) disease. Recently, the role of immune activation in HIV disease progression and response to treatment is being investigated. This study focused on the expression of CD38 and HLA-DR on lymphocyte subsets in various groups of HIV-infected individuals and to determine their association with HIV-1 disease progression. METHODS: Ninety-eight cases of patients with HIV/AIDS in different disease stages and twenty-four healthy HIV-negative individuals were included in the cross-sectional study. Their immune function and abnormal immune activation markers (CD38 & HLA-DR) were detected using a flowcytometer, and HIV-1 RNA levels in individuals receiving antiretroviral drugs were estimated. RESULTS: The immune activation marker levels were significantly different between patients with different disease stages (P < 0.001). A significant negative correlation was observed between peripheral blood CD4+ T cell counts and immune activation markers. Also, a significant positive correlation was observed between HIV-1 RNA levels and CD38+CD8+ T lymphocyte. CONCLUSION: Immune activation markers (CD38 & HLA-DR) increase with disease progression. CD38+ on CD8+ T lymphocyte correlates well with HIV1 RNA levels in individuals failing on antiretroviral therapy.
BACKGROUND: Currently CD4+ T lymphocyte counts and HIV-1 RNA levels are being utilized to predict outcome of human immunodeficiency virus (HIV) disease. Recently, the role of immune activation in HIV disease progression and response to treatment is being investigated. This study focused on the expression of CD38 and HLA-DR on lymphocyte subsets in various groups of HIV-infected individuals and to determine their association with HIV-1 disease progression. METHODS: Ninety-eight cases of patients with HIV/AIDS in different disease stages and twenty-four healthy HIV-negative individuals were included in the cross-sectional study. Their immune function and abnormal immune activation markers (CD38 & HLA-DR) were detected using a flowcytometer, and HIV-1 RNA levels in individuals receiving antiretroviral drugs were estimated. RESULTS: The immune activation marker levels were significantly different between patients with different disease stages (P < 0.001). A significant negative correlation was observed between peripheral blood CD4+ T cell counts and immune activation markers. Also, a significant positive correlation was observed between HIV-1 RNA levels and CD38+CD8+ T lymphocyte. CONCLUSION: Immune activation markers (CD38 & HLA-DR) increase with disease progression. CD38+ on CD8+ T lymphocyte correlates well with HIV1 RNA levels in individuals failing on antiretroviral therapy.
Authors: J Carbone; J Gil; J M Benito; J Navarro; A Muñóz-Fernández; J Bartolomé; J M Zabay; F López; E Fernández-Cruz Journal: AIDS Date: 2000-12-22 Impact factor: 4.177
Authors: M Vajpayee; S Kaushik; V Sreenivas; K Mojumdar; S Mendiratta; N K Chauhan Journal: Eur J Clin Microbiol Infect Dis Date: 2008-07-09 Impact factor: 3.267
Authors: S Zolla-Pazner; D C Des Jarlais; S R Friedman; T J Spira; M Marmor; R Holzman; D Mildvan; S Yancovitz; U Mathur-Wagh; J Garber Journal: Proc Natl Acad Sci U S A Date: 1987-08 Impact factor: 11.205
Authors: Rafael Tibúrcio; Beatriz Barreto-Duarte; Gopolan Naredren; Artur T L Queiroz; Selvaraj Anbalagan; Kaustuv Nayak; Narayanan Ravichandran; Rajasekaran Subramani; Lis R V Antonelli; Kumar Satagopan; Komathi Anbalagan; Brian O Porter; Alan Sher; Soumya Swaminathan; Irini Sereti; Bruno B Andrade Journal: Front Immunol Date: 2021-10-07 Impact factor: 7.561